Table 2.
Individual results from baseline (pre) and follow-up after 12 weeks (post) of Glossopharyngeal Insufflation for the six patients fulfilling the study protocol.
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| VC1, L | 4.84 | 5.18 | 5.63 | 4.94 | 3.68 | 3.95 | 3.11 | 3.14 | 5.79 | 5.69 | 5.56 | 5.89 |
| PEF2, L/min | 557 | 605 | 545 | 539 | 561 | 528 | 589 | 559 | 586 | 491 | 625 | 656 |
| C7-30, cm | 5.0 | 5.5 | 6.0 | 5.5 | 3.5 | 3.5 | 0.5 | 1.0 | 3.0 | — | 2.0 | 4.0 |
| Tragus-wall, cm | 10 | 9.5 | 11.5 | 11.5 | 11.5 | 11.0 | 18 | 17.0 | 10.5 | — | 16 | 13..5 |
| BX3 diff, cm | 7.0 | 8.5 | 6.0 | 7.5 | 2.0 | 4.0 | 4.0 | 5.0 | 6.0 | — | 7.0 | 9.5 |
| BC4 diff, cm | 9.5 | 11.5 | 4.5 | 6.5 | 3.0 | 3.5 | 2.0 | 2.0 | 4.0 | — | 6.0 | 8.0 |
| BAS DAI5, 0–10 | 3.4 | 3.4 | 0.4 | 1.3 | 1.8 | 2.0 | 1.5 | 2.3 | 2.3 | — | 0.7 | 0.8 |
| BASFI6, 0–10 | 0.6 | 0.25 | 0.2 | 0.7 | 1.5 | 2.0 | 1.0 | 1.0 | 1.1 | — | 2.1 | 1.9 |
| BASG17, 0–10 | 1.6 | 2.4 | 0.4 | 2.6 | 2.5 | 2.3 | 0.2 | 0.3 | 1.9 | — | 0.6 | 1.2 |
| VCGI8 (L) | 6.75 | 5.40 | 4.05 | 3.57 | 5.76 | 7.78 | ||||||
| VC increase with GI (%) | 30.3 | 1.4 | 2.5 | 13.7 | 1.2 | 32.1 | ||||||
1Vital capacity (VC), 2peak expiratory flow (PEF), 3level of xiphoid process on the chest wall (BX) difference of inhalation and exhalation, 4level of the fourth costae on the chest wall (BC) difference of inhalation and exhalation, 5the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 6the Bath Ankylosing Spondylitis Functional Index (BASFI), 7the Bath Ankylosing Spondylitis Global Index (BASG1), and 8vital Capacity using Glossopharyngeal Insufflation (VCGI).